中国经济网编者按:1月14日,湖南南新制药股份有限公司(以下简称“南新制药”)首发上会。南新制药拟登陆上交所科创板,公开发行股票的数量不超过3500万股,保荐机构为。南新制药拟募集资金亿元,用于创新药研发项目、营销渠道网络升级建设项目、补充流动资金。

China Economic Network Editor according to: January 14, Hunan Nanxin Pharmaceutical Co., Ltd.(hereinafter referred to as \"Nanxin Pharmaceutical \") the first meeting. South new pharmaceuticals to land on the division, the number of public offerings of no more than 35 million shares, the sponsor. Nanxin pharmaceuticals to raise 100 million yuan for innovative drug research and development projects, marketing channel network upgrade construction projects, supplementary liquidity.

  2016年至2019年1-6月,南新制药实现营业收入分别为亿元、亿元、亿元、亿元,归属于母公司股东的净利润分别为万元、万元、万元、万元,扣除非经常性损益后归属于母公司股东的净利润分别为万元、万元、万元、万元。

From 2016 to January 2019, the operating income of Nanxin Pharmaceutical was 100 million yuan,100 million yuan,100 million yuan and 100 million yuan respectively, and the net profit attributable to the shareholders of the parent company was 10,000 yuan,10,000 yuan,10,000 yuan and 10,000 yuan respectively.

  公司研发投入占比低于行业均值。2016年至2019年1-6月,南新制药研发投入金额分别为万元、万元、万元、万元,研发投入占营业收入的比例分别为%、%、%、%,同行业可比公司研发投入/营业收入比分别为%、%、%、%。公司累计研发投入占累计营业收入比为%,低于行业均值%。

The proportion of R
欢迎转载,转载请注明出处:威尼斯人棋牌app